Assembly Biosciences to effect 1-for-12 reverse stock split on February 9

Assembly Biosciences expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common stock will begin trading on a split-adjusted basis on The Nasdaq Global Select Market under the same symbol when the market opens on February 12, 2024, with the new CUSIP number 045396207. As of the effective time of the reverse stock split, every 12 issued and outstanding shares of the company’s common stock will be automatically reclassified into one issued and outstanding share of the company’s common stock. This will reduce the number of shares outstanding from approximately 65.8 million shares to approximately 5.5 million, subject to adjustment for fractional shares. The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.